Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seirogan for Metformin-Induced Diarrhoea in Type 2 Diabetes
jRCTs041220146Recruiting
- Sponsor
- Taiko Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Seirogan Quick C in type 2 diabetes mellitus (T2DM) and diarrhea (2 arms), sponsored by Taiko Pharmaceutical Co., Ltd. Primary endpoint: Number of days of diarrhoea from baseline to 4 weeks. Started Feb 2023; status: recruiting.
02
Drugs
Seirogan Quick C
03
Conditions
type 2 diabetes mellitus (T2DM)diarrhea
Beyond the preview
Go deeper on jRCTs041220146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220146.